Search This Blog

Friday, January 31, 2020

Bayer Gets EU Panel Recommendation for Prostate Cancer Treatment

Bayer AG said Friday that the European Union’s Committee for Medicinal Products for Human Use has given a positive opinion on its darolutamide medicine as a new treatment for men with a particular type of prostate cancer.
The compound–jointly developed with ORION Corp. (271560.SE)–is recommended for men with non-metastatic castration-resistant prostate cancer who have a high risk of developing metastatic disease, the pharmaceutical firm said.
In most cases a recommendation leads to marketing approval. Bayer said that it expects a decision to be made in the coming months.

https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Gets-EU-Medicines-Agency-Recommendation-for-Prostate-Cancer-Treatment-29920247/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.